Endocrine Abstracts

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by variable combination of more than 20 types of endocrine and non-endocrine tumors: typically parathyroid glands, pancreatic islet cells and anterior pituitary gland are involved. We studied 20 patients (10M and 10F), affered to our Pituitary Unit in a period of 10 years. All patients had clinical diagnostic criteria suspected for MEN1 (presence of two endocrine tumors at least) and und...

PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than SSA. We investigated the role of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours. We evaluated 55 patients with well or moderately differentiated neuroendocrine tumours; 31 patients with either metastatic, unresectable or functioning tumours were ...

GH excess is considered as one of the causes of secondary osteoporosis with an increased risk of vertebral fractures in men and post-menopausal women with acromegaly. GH excess in acromegaly is also frequently associated with type 2 diabetes which is considered as a risk factor for fragility fractures in the general population. In this cross-sectional study, we evaluated whether type 2 diabetes may influence the prevalence vertebral fractures in acromegaly. Fifty-seven males w...

Hyperprolactinemia may cause bone loss in pre-menopausal women and men. Data on fractures are scanty and it is still unclear which is the skeletal impact of hyperprolactinemia in post-menopausal women. The aim of this study was to evaluate the prevalence of vertebral fractures in post-menopausal women with hyperprolactinemia.Forty post-menopausal women (median age 57 years, range: 47–81) with prolactin (PRL)-secreting adenoma and 119 control post-me...

Patients with acromegaly resistant to conventional drug treatment currently can advantage with GH-receptor antagonist pegvisomant. To date, at doses up to 40 mg/day, it is capable of normalizing circulating IGF1 in until 97% of patients. Here we present the multicenter experience in Rome with Pegvisomant as a therapeutic option in acromegaly. This is an observational study including a total of 61 patients (21 males and 40 females) treated with pegvisomant for up to 7 years. Of...

Insulin sensitivity in GHD patients tends to decrease with age and variations in body composition. Several indices of insulin sensitivity have been considered and among these HOMA, ISI and QUICKI are based on mathematical calculations taking into account glucose and/or insulin levels either in basal conditions or after OGTT. Aim of present study was to validate the different indices in a population of pre-pubertal GHD children (n=66) by ROC curve analysis. All patients ...

ACROSTUDY is an international observational study to evaluate efficacy and safety of long-term treatment with pegvisomant (PEGA) in acromegaly. ACROSTUDY Italy was started in 2007 and we report data from the first 185 patients (93M, 92F, mean age, range, 49.9 y; 17–83.8 y) treated with PEGA (mean duration, range, 3.2 y, 0.1–8.5 y), from 24 centers, until 01/2010. Before and during PEGA, IGF1, GH-Ab, liver enzymes, metabolic parameters and pituitary MRI were assessed....

Introduction: Neuroendocrine neoplasms are rare and multiform requiring a multidisciplinary approach. We report the experience of a Neuroendocrine tumor board (TB) established at our University Hospital.Aims: The aim is to share clinical and diagnostic data for best decision-making according to the existing ENETS guidelines.Materials and methods: According to the indications for ENETS Centers of Excellence, meetings with experts in...

In order to investigate the correlations between immunohistochemical picture with proliferative index (Ki-67), the clinical course and outcome of GH-secreting pituitary adenomas not cured by neurosurgery, we studied 41 consecutive acromegalic patients (M 12, F 29; aged 43±10.8 yr) previously undergone neurosurgical resection of adenoma. Two patients underwent neurosurgical intervention at least twice. Post-surgical follow-up ranged from 6 to 36 months and all patients rec...

Introduction: Medullary thyroid carcinoma (MTC) and C cell hyperplasia (CCH) have a variable clinical presentation and prognosis and few data are available on the correlation between immunohistochemical characterization (IIC) and clinical behavior.Aim: We studied the clinical and morphological characterization of CCH and MTC and we evaluated IIC expression of PTTG-1, SSTR2A, VEGFR-1, VEGFR-2 and VEGFR-3 in 23 cases of CCH and/or MTC, correlating it with ...